Show simple item record

Pacientes elegibles para las nuevas terapias de la insuficiencia cardíaca en un policlínico especializado

dc.contributores-ES
dc.creatorRossel, Víctor; Hospital del Salvador. Universidad de Chile
dc.creatorDuarte, Manuel; Universidad de Chile
dc.creatorMuñoz, Pilar; Universidad de Chile Hospital del Salvador
dc.creatorBravo, Catherine; Hospital del Salvador
dc.creatorBobadilla, Gustavo; Universidad de Los Andes
dc.creatorVerdugo, Fernando; Universidad de Chile
dc.creatorGuardamagna, Carmen; Hospital del Salvador
dc.date2019-01-10
dc.date.accessioned2019-11-11T18:26:50Z
dc.date.available2019-11-11T18:26:50Z
dc.identifierhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/view/6832
dc.identifier.urihttps://revistaschilenas.uchile.cl/handle/2250/110866
dc.descriptionBackground: Pharmacological treatment improves survival in patients with heart failure with reduced ejection fraction. The use of sacubutril / valsartan and ivabradine has been recently approved and incorporated in the latest guidelines. Aim: To identify candidates eligible for these therapies among patients treated in a heart failure clinic, considering the inclusion criteria for the PARADIGM-HF and SHIFT trials. Material and methods: Cross-sectional study in 158 patients aged 62 ± 11 years (67% male) with heart failure and reduced ejection fraction, with at least three months of follow-up and without decompensation. The percentage of patients complying for the inclusion criteria for the PARADIGM-HF y SHIFT trials was determined. Results: In 37%, the etiology of heart failure was ischemic, 49% were in functional class I, their ejection fraction was 33 ± 11% and their median Pro-brain natriuretic peptide was 800 pg/mL. Ninety five percent were treated with vasodilators, 97% with beta-blockers and 82% with aldosterone antagonists. Using PARADIGM-HF and SHIFT criteria, 11 patients (7%) were eligible for sacubitril / valsartan and 21 patients (13.3%) for ivabradine. Among the main causes of non-eligibility for sacubitril / valsartan were being functional class I (48.7%) and not achieving a stable dose of enalapril ? 20 mg / day or losartan ? 100 mg / day (24.7%). In the case of ivabradine, apart from those in functional class I, the absence of sinus rhythm and a heart ratees-ES
dc.formatapplication/pdf
dc.languagespa
dc.publisherRevista Médica de Chilees-ES
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/view/6832/4793
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6832/35453
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6832/35454
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6832/35455
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6832/35456
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6832/35457
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6832/35458
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6832/35459
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6832/35460
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6832/35461
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6832/35674
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6832/37744
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6832/37745
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6832/37746
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6832/40300
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6832/40412
dc.sourceRevista Médica de Chile; Vol. 147, núm. 3 (2019): MARZO 2019es-ES
dc.source0034-9887
dc.subjectDrug Therapy; Heart Diseases; Heart Failurees-ES
dc.titlePacientes elegibles para las nuevas terapias de la insuficiencia cardíaca en un policlínico especializadoes-ES
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.typees-ES


This item appears in the following Collection(s)

Show simple item record